Docket No.: 03991/0204241-US0

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mark Guthridge et al.

Application No.: 10/595,559 Confirmation No.: 2795

Filed: April 27, 2006 Art Unit: N/A

For: A BINDING MOTIF AND METHODS OF

REGULATING CELL FUNCTION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the date of entry of the national stage of an international application as set forth in 37 CFR 1.491 (37 CFR 1.97(b)(2)).

A copy of only those documents listed below is attached:

For. Doc No.	Ctry	Patentee/Applicant	Publication Date
2005/040198	PC	Medvet Science Pty Ltd.	May 6, 2005

Application No.: 10/595,559 2 Docket No.: 03991/0204241-US0

Other Documents

DATABASE NCB (protein) Accession NUmber: AAA18171, 16 May 1994

Bone, H. et al., "She associates with the IL-3 receptor b submit, SHIP and Gab2

Stomski F.C. et al., " Identification of a 14-3-3 Binding Sequence in the

Guthridge, M.A. et al., "Mechanism of activation of the GM-CSF, IL-3, and IL-

Itoh, T. et al., "Granulocyte-macrophage colony-stimulating factor provokes

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: April 28, 2006

Respectfully submitted,

3y $\sqrt{53}$

Chandra Garry

Registration No.: 57,895 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/595,559-Conf. #2795	
11	NFORMATION	l Di	SCLOSURE	Filing Date	April 27, 2006	
l s	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Mark Guthridge	
				Art Unit	N/A	
				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	03991/0204241-US0	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Publication Date Number-Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		•			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	BA	WO-2005/040198-A1	05-06-2005	Medvet Science Pty Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	CA	DATABASE NCB (protein) Accession NUmber: AAA18171, 16 May 1994 GM-CSF receptor beta chain, Pgs 1- 2.				
	СВ	Bone, H. et al., "Shc associates with the IL-3 receptor β submit, SHIP and Gab2 following IL-3 stimulation: Contribution of Shc PTB and SH2 domains", Cellular Signalling, 2000, Vol. 12, Pages 183-194.				
	CC	Stomski F.C. et al., "Identification of a 14-3-3 Binding Sequence in the Common β Chain of the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-3 (IL-3), and IL-5 Receptors That is Serine-Phosphorylated by GM-SCF", Blood, 1999, vol. 94 (number 6), pages 1933-1942.				
	CD	Guthridge, M.A. et al., "Mechanism of activation of the GM-CSF, IL-3, and IL-5 Family of Receptors", Stem Cells, 1998, Vol. 16, Pages 301-313.				
	CE	Itoh, T. et al., "Granulocyte-macrophage colony-stimulating factor provokes RAS activation and transcription of c-fos through different modes of signalling "The Journal of Biological Chemistry, 1996, Vol. 271 (number 13), pages 7587 - 7592.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Examiner	Date
Signature	Considered
0.3	

¹Applicant's unique citation designation number (optional). ²Applicant Is to place a check mark here if English language Translation is attached.